Drug Trial Radar · NCT03627468
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Last checked: Nov 20, 2026Latest source record: May 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Sep 5, 2018
Primary completion
Jan 27, 2020
Study completion Jan 27, 2020
Sponsor
- Lead sponsor
- Botanix PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of the sweat glands. Current therapies have limited effectiveness, significant side effects, and can be invasive and costly. Sofpironium bromide (BBI-4000) is a novel soft-drug in development for the topical treatment of hyperhidrosis. This Phase 3 study will assess the long-term safety, tolerability, and efficacy of sofpironium bromide gel applied topically to subjects with axillary hyperhidrosis.
Conditions
- Primary Axillary Hyperhidrosis
Interventions
Sofpironium Bromide Gel, 5%Drug
Sofpironium Bromide Gel, 5%
Sofpironium Bromide Gel, 15%Drug
Sofpironium Bromide Gel, 15%
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Participants With Treatment Emergent Adverse Events Cumulative to Week 48 by Maximum SeverityTime frame: All safety subjects, reaching week 48 or not
- Number of Participants With Post-baseline Local Tolerability Assessments Results by Treatment Group (Population: Safety)Time frame: All Safety Subject, Baseline-Through study completion (48 weeks) or Not
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Coastal Clinical Research, Inc.
Mobile, Alabama
Northwest Arkansas Clinical Trials Center
Rogers, Arkansas
Center for Clinical and Cosmetic Research
Aventura, Florida
Skin Care Research, Inc.
Boca Raton, Florida
Baumann Cosmetic & Research Institute
Miami, Florida
Tory Sullivan MD PA
North Miami Beach, Florida
Research Institute of the Southeast, LLC
West Palm Beach, Florida
Grekin Skin Institute
Warren, Michigan
Minnesota Clinical Study Center
Fridley, Minnesota
Tennessee Clinical Research Center
Nashville, Tennessee
J&S Studies, Inc.
College Station, Texas
Austin Institute for Clinical Research
Pflugerville, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.